Fast Five Quiz: Primary Hyperoxaluria Type 1 Management

Bradley Schwartz, DO


March 04, 2022

RNA interference is a naturally occurring cellular mechanism for regulating gene expression mediated by small interfering RNAs. Recent data suggest that this may be a beneficial approach for reducing oxalate production in patients with PH1. The RNA inhibitor lumasiran was approved in 2020 for PH1.

Early studies have suggested pluripotent stem cell-based therapies may be beneficial in PH1. Enzyme restoration therapy, gene editing, and inflammasome inhibitors have shown evidence of efficacy in preclinical studies, but to date, no compounds are under investigation in humans.

Preliminary data were promising, but no evidence from controlled trials currently supports the use of oral Oxalobacter formigenes therapy in the management of PH1.

Learn more about the diagnosis and management of PH1.

Editor's Recommendations


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.